Peptide storage is about slowing down the chemical and physical changes that break peptides down over time, and the four main factors are temperature, light, moisture and oxygen. Peptides are generally kept cold, dry, protected from light and sealed from air, because each of these factors can speed up degradation. But the right conditions are specific to each product, and they are established by stability testing, not guesswork.
This article explains the science behind each factor and how laboratories and regulators decide what storage conditions a peptide needs. It is educational background, not a set of handling instructions.
Key Takeaways
- Heat, light, moisture and oxygen are the main environmental drivers of peptide degradation [1][2].
- For medicines, storage conditions and shelf life come from formal stability studies, guided internationally by ICH guidelines [3][4].
- Peptides are generally stored refrigerated or frozen to minimise degradation, according to the European Medicines Agency [1].
- Many peptide powders are hygroscopic: they pull moisture from the air [1].
- Certain amino acids, such as methionine, cysteine and tryptophan, are especially vulnerable to oxidation and light [2][5].
Why Peptide Storage Conditions Matter
Every peptide is slowly changing, even in a sealed container. Chemical reactions such as oxidation, deamidation and hydrolysis gradually convert the intended molecule into related impurities. Physical changes, such as aggregation (molecules clumping together), can also occur [1][6]. Our guide on how peptides degrade explains these reactions in detail.
Storage cannot stop these processes, but it can slow them dramatically. A useful distinction: shelf life is how long a product stays within specification in storage, whereas half-life usually describes how quickly a peptide is cleared or broken down in the body. They are different concepts.
Factor 1: Temperature
As a general rule of chemistry, reactions run faster at higher temperatures. That is why cold storage is the default for many peptides. The European Medicines Agency's 2025 guideline on synthetic peptides states that, generally, peptides are stored refrigerated (5°C ± 3°C) or frozen (−20°C ± 5°C) to prevent or minimise degradation, with testing at higher temperatures to understand the effect of short-term excursions [1]. (This is an EU guideline for medicines, applicable since 1 June 2026; other jurisdictions set their own requirements.)
Excursions and shipping
Temperature problems often happen in transit rather than in storage. The FDA, for example, has reported complaints about certain compounded injectable GLP-1 products arriving warm or with inadequate ice packs, and has cautioned that this can affect a drug's quality [7].
Freezing is not automatically harmless
Freezing slows chemistry, but the freezing process itself can stress some molecules. Reviews of protein freeze-drying describe freezing stresses that can damage proteins to varying degrees [8]. This is one reason manufacturers study how their specific product responds to freezing.
Factor 2: Light
Light, especially ultraviolet light, carries enough energy to trigger chemical reactions in some amino acids. A review of protein photodegradation identifies tryptophan, tyrosine, phenylalanine and cysteine/cystine as the residues that undergo primary photo-oxidation, and notes that these changes could alter structure and stability [5]. Light can also help trigger oxidation more generally [2].
Regulators treat light as a formal test variable. ICH Q1B sets out photostability testing for new medicines. For confirmatory studies, samples are exposed to at least 1.2 million lux hours of visible light and 200 watt-hours per square metre of near-ultraviolet energy, so that results can be compared across products [9]. The outcome helps decide whether a product needs light-protective packaging or a "protect from light" label.
Factor 3: Moisture
Water is a reactant in hydrolysis and helps molecules move and react. This is one reason peptides are often freeze-dried; see what is lyophilization?.
Dry powders bring their own challenge. The EMA notes that peptides are often very hygroscopic powders, meaning they readily absorb water from the air [1]. It expects water content to be monitored in stability studies of hygroscopic peptides and suggests that desiccants or storage under an inert atmosphere may be considered for packaging [1].
The relationship between moisture and stability is not always simple. In one study of a freeze-dried antibody formulation, degradation appeared lowest at about 2–3% water content rather than at the lowest possible moisture [10]. That finding applies to that formulation, but it shows why moisture is measured and controlled rather than assumed.
Factor 4: Oxygen
Oxidation is one of the major chemical degradation pathways for proteins and peptides. Methionine, cysteine, histidine, tryptophan and tyrosine are the residues most susceptible, and oxidation can be triggered by contaminating oxidants, catalysed by traces of metal ions, or induced by light [2]. The EMA highlights oxidation of cysteine and methionine as degradation pathways to consider for peptides [1].
Ways to limit oxygen exposure in manufacturing include well-sealed containers and packaging under an inert atmosphere [1]. A 2023 review of peptide formulation lists "air exclusion" among practical strategies to slow peptide degradation in solution [11].
Solid vs. Solution
Peptides are generally more vulnerable in solution than as a dry powder. The same 2023 review notes that peptides are often unstable in aqueous solutions, and identifies optimising pH and choosing the right buffer as the most practical ways to stabilise them in liquid formulations [11]. This is why many peptide medicines and research materials are supplied dry, while liquid medicines are carefully formulated and labelled with specific storage and in-use instructions.
At a Glance: Storage Factors and Why They Matter
| Factor | Main effect | Amino acids or features most affected | Typical protective measure |
|---|---|---|---|
| Heat | Speeds up most degradation reactions | All; aggregation-prone sequences | Refrigerated or frozen storage [1] |
| Light | Photo-oxidation | Trp, Tyr, Phe, Cys [5] | Light-protective packaging where testing shows it is needed [9] |
| Moisture | Hydrolysis, increased molecular mobility | Hygroscopic powders [1] | Sealed containers, desiccants [1] |
| Oxygen | Oxidation | Met, Cys, His, Trp, Tyr [2] | Sealed containers, inert gas [1] |
How Storage Conditions Are Decided
For regulated medicines, storage instructions are not arbitrary. They come from stability studies designed according to international guidelines:
- ICH Q1A(R2) defines the stability data needed for new drug substances and products [3]. For the general case, long-term studies are run at 25°C/60% relative humidity (or 30°C/65%), and accelerated studies at 40°C/75% relative humidity [12]. Separate conditions apply to products meant to be refrigerated or frozen.
- ICH Q5C covers stability testing for biotechnological and biological products, including well-characterised proteins and polypeptides [4].
- ICH Q1B covers photostability [9].
These guidelines are being updated. ICH is consolidating its stability guidelines into a single revised Q1 guideline, with final adoption scheduled for late 2026 according to the working group's published plan [13]. Readers should check which version applies.
For peptides specifically, the EMA also expects forced degradation studies, in which samples are deliberately stressed to reveal how they break down and to prove that analytical methods can detect the resulting impurities [1].
Regulatory Status
Storage and labelling requirements for medicines are set by each jurisdiction's regulator, for example the FDA in the United States, the EMA and national authorities in the European Union, the MHRA in the UK, the TGA in Australia and Health Canada. Most follow ICH stability principles, but details can differ. Regulatory status varies by jurisdiction and may change over time. Consult the relevant regulatory authority for current information. For any specific product, the labelled storage conditions from the manufacturer or the product information approved by a regulator take precedence over general guidance.
Frequently Asked Questions
Why are peptides usually stored cold?
Chemical degradation generally slows at lower temperatures. The EMA notes that peptides are generally stored refrigerated or frozen to prevent or minimise degradation [1].
Does light really damage peptides?
It can. Amino acids such as tryptophan, tyrosine, phenylalanine and cysteine are susceptible to photo-oxidation [5]. Photostability testing under ICH Q1B determines whether light protection is needed [9].
What does "hygroscopic" mean?
It means a material readily absorbs moisture from the air. Many peptide powders are hygroscopic, so exposure to humid air can raise their water content [1].
Is a freeze-dried peptide safe from degradation?
It is usually more stable than a solution, but not immune. Solid-state degradation still occurs, which is why dried products also have defined storage conditions and shelf lives [8].
Who decides the storage conditions on a medicine label?
The manufacturer proposes them based on stability data, and the regulator in each jurisdiction reviews them as part of the approval process [3].
References
- European Medicines Agency. Guideline on the Development and Manufacture of Synthetic Peptides (EMA/CHMP/CVMP/QWP/367182/2025). https://www.ema.europa.eu/en/development-manufacture-synthetic-peptides-scientific-guideline ↗
- Li S, Schöneich C, Borchardt RT. Chemical instability of protein pharmaceuticals: mechanisms of oxidation and strategies for stabilization. Biotechnol Bioeng. 1995;48(5):490-500. https://doi.org/10.1002/bit.260480511 ↗
- European Medicines Agency. ICH Q1A(R2) Stability testing of new drug substances and drug products - Scientific guideline. https://www.ema.europa.eu/en/ich-q1a-r2-stability-testing-new-drug-substances-drug-products-scientific-guideline ↗
- European Medicines Agency. ICH Q5C Stability testing of biotechnological/biological products - Scientific guideline. https://www.ema.europa.eu/en/ich-q5c-stability-testing-biotechnologicalbiological-products-scientific-guideline ↗
- Kerwin BA, Remmele RL Jr. Protect from light: photodegradation and protein biologics. J Pharm Sci. 2007;96(6):1468-1479. https://doi.org/10.1002/jps.20815 ↗
- Zapadka KL, Becher FJ, Gomes Dos Santos AL, Jackson SE. Factors affecting the physical stability (aggregation) of peptide therapeutics. Interface Focus. 2017;7(6):20170030. https://doi.org/10.1098/rsfs.2017.0030 ↗
- U.S. Food and Drug Administration. FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss. https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss ↗
- Wang W. Lyophilization and development of solid protein pharmaceuticals. Int J Pharm. 2000;203(1-2):1-60. https://doi.org/10.1016/s0378-5173(00)00423-3 ↗
- ICH. Q1B Stability Testing: Photostability Testing of New Drug Substances and Products. https://database.ich.org/sites/default/files/Q1B%20Guideline.pdf ↗
- Chang LL, Shepherd D, Sun J, Tang XC, Pikal MJ. Effect of sorbitol and residual moisture on the stability of lyophilized antibodies. J Pharm Sci. 2005;94(7):1445-1455. https://doi.org/10.1002/jps.20363 ↗
- Nugrahadi PP, Hinrichs WLJ, Frijlink HW, Schöneich C, Avanti C. Designing formulation strategies for enhanced stability of therapeutic peptides in aqueous solutions: a review. Pharmaceutics. 2023;15(3):935. https://doi.org/10.3390/pharmaceutics15030935 ↗
- ICH. Q1A(R2) Stability Testing of New Drug Substances and Products. https://database.ich.org/sites/default/files/Q1A%28R2%29%20Guideline.pdf ↗
- ICH. Q1 EWG Work Plan (February 2026). https://database.ich.org/sites/default/files/ICH52_Q1_EWG_WorkPlan_2026_0318.pdf ↗
This article is for educational purposes only and is not medical advice. It does not provide instructions for handling, preparing or using any product. For health decisions, consult a qualified healthcare professional, and for regulatory questions, consult the medicines regulator in your jurisdiction.